Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Tofacitinib improved hair and nail conditions in a teen with alopecia areata.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

Compound 4 is a promising treatment for hair loss with low toxicity.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Erlotinib can cause nonscarring hair loss and itchy skin.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Topical Ruxolitinib may safely treat severe hair loss.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Patients with alopecia areata on ritlecitinib responded well to tetanus and meningococcal vaccines.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

Activated ras can protect kidney cells from a certain substance that causes cell death.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.